ecrin-mdr-crcClinical2022IPD Sharing (as of April 2022): Yes Description: The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research. Time frame: Data can be shared no earlier than 1 year following the date of publication Access Criteria: Contact the Partners Innovations team at http://www.partners.org/innovation Additional information available: Study Protocol, Statistical Analysis Plan, Informed Consent FormColorectal CancerColorectal NeoplasmsSalicylatesColorectal CancerColorectal NeoplasmsSalicylatesInterventionalhttps://newmdr.ecrin.org/Study/2390610United States3AspirinSalicylic AcidECRIN MDRRecruitingfalseASPIRED-XT: ASPirin Intervention for the REDuction of Colorectal Cancer Risk -EXTensionThis research study is studying a drug intervention as a possible chemoprevention strategy for colorectal cancer. The name of the study intervention involved in this study is: * Low Dose Aspirin2022-03-152390610NCT05056896